Go to
JCI Insight
Citations to this article
Rick Bucala
Published May 1, 2014
Citation Information: J Clin Invest. 2014;124(5):1887-1888. https://doi.org/10.1172/JCI75224.
Citation Information: J Clin Invest. 2014;124(5):1887-1888. https://doi.org/10.1172/JCI75224.
Abstract
The inactivation of NO by advanced glycation endproducts (AGEs), which accumulate on tissue proteins as a function of age and hyperglycemia, focused attention on the role of these ubiquitous posttranslational modifications in acquired impairments of vascular reactivity and other signaling processes. This observation occurred during a watershed period of basic and translational research in glycation that encompassed new pathologic phenomena and novel intervention strategies. How has the AGE paradigm for the tissue complications of aging and diabetes fared since the identification of the link between these glycation products and NO inactivation, and what lessons may be offered for future investigations?
Authors
Rick Bucala
Total citations by year
Citation information
Citations to this article (19)
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)